Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2009 2
2011 1
2012 2
2013 1
2014 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Kays MB, Fleming MR, Cheatham SC, Chung EK, Juenke JM. Kays MB, et al. Ann Pharmacother. 2014 Feb;48(2):178-86. doi: 10.1177/1060028013512474. Epub 2013 Nov 14. Ann Pharmacother. 2014. PMID: 24259653 Clinical Trial.
BACKGROUND: Antimicrobial pharmacokinetic and pharmacodynamic data are limited in obesity. OBJECTIVE: To evaluate the steady-state pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients hospitalized on a general ward. ...Difference …
BACKGROUND: Antimicrobial pharmacokinetic and pharmacodynamic data are limited in obesity. OBJECTIVE: To evaluate the steady-state …
Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.
Cirillo I, Vaccaro N, Turner K, Solanki B, Natarajan J, Redman R. Cirillo I, et al. J Clin Pharmacol. 2009 Jul;49(7):798-806. doi: 10.1177/0091270009337012. J Clin Pharmacol. 2009. PMID: 19553404 Clinical Trial.
The pharmacokinetics, safety, and tolerability of doripenem in healthy subjects were evaluated in 2 studies. ...Doripenem exhibited linear pharmacokinetics with concordance between the studies for pharmacokinetic parameters. ...
The pharmacokinetics, safety, and tolerability of doripenem in healthy subjects were evaluated in 2 studies. ...Doripenem …
Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia.
Stein GE, Kulhanek G, Smith CL, Kuti JL, Nicolau DP, Scharmen A, Farnum C, Tran M, Kalra A, Havlichek DH. Stein GE, et al. Ann Pharmacother. 2012 Oct;46(10):1281-6. doi: 10.1345/aph.1R097. Epub 2012 Sep 25. Ann Pharmacother. 2012. PMID: 23012385 Clinical Trial.
There is a paucity of pharmacokinetic/pharmacodynamic data on doripenem in patients with febrile neutropenia. OBJECTIVE: To conduct a pharmacokinetic evaluation of 2 doses of doripenem in patients with febrile neutropenia and provide probability estima …
There is a paucity of pharmacokinetic/pharmacodynamic data on doripenem in patients with febrile neutropenia. OBJECTIVE: To co …
Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
Jaruratanasirikul S, Wongpoowarak W, Kositpantawong N, Aeinlang N, Jullangkoon M. Jaruratanasirikul S, et al. Int J Antimicrob Agents. 2012 Nov;40(5):434-9. doi: 10.1016/j.ijantimicag.2012.07.014. Epub 2012 Sep 7. Int J Antimicrob Agents. 2012. PMID: 22959555 Clinical Trial.
Several pathophysiological changes in critically ill patients are important in determining the therapeutic success of beta-lactam antibiotics. The aim of this study was to assess the population pharmacokinetics and probabilities of target attainment (PTAs) of doripenem …
Several pathophysiological changes in critically ill patients are important in determining the therapeutic success of beta-lactam antibiotic …
Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem.
Cirillo I, Vaccaro N, Balis D, Redman R, Matzke GR. Cirillo I, et al. Antimicrob Agents Chemother. 2011 Mar;55(3):1187-93. doi: 10.1128/AAC.01063-10. Epub 2011 Jan 3. Antimicrob Agents Chemother. 2011. PMID: 21199922 Free PMC article. Clinical Trial.
In dialysis-dependent subjects, levels of systemic exposure to doripenem and doripenem-M-1 were approximately 3- and 5-fold greater, respectively, than those in healthy subjects: for doripenem, 98 mug.h/ml for CVVH and 77 mug.h/ml for CVVHDF versus 32 mug.h/m …
In dialysis-dependent subjects, levels of systemic exposure to doripenem and doripenem-M-1 were approximately 3- and 5-fold gr …
Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.
Wagenlehner FM, Wagenlehner C, Redman R, Weidner W, Naber KG. Wagenlehner FM, et al. Antimicrob Agents Chemother. 2009 Apr;53(4):1567-73. doi: 10.1128/AAC.01133-08. Epub 2009 Feb 2. Antimicrob Agents Chemother. 2009. PMID: 19188391 Free PMC article. Clinical Trial.
UBTs and AUBTs are pharmacokinetic/pharmacodynamic parameters able to reflect the activity of an antimicrobial substance in the urine. ...Eight microbiological failures were observed, three after doripenem treatment and five after levofloxacin treatment. For levoflo …
UBTs and AUBTs are pharmacokinetic/pharmacodynamic parameters able to reflect the activity of an antimicrobial substance in the urine …
Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.
Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Bhavnani SM, et al. Antimicrob Agents Chemother. 2005 Sep;49(9):3944-7. doi: 10.1128/AAC.49.9.3944-3947.2005. Antimicrob Agents Chemother. 2005. PMID: 16127078 Free PMC article. Clinical Trial.
A doripenem population pharmacokinetic model and Monte Carlo simulations were utilized for dose regimen decision support for future clinical development. Simulation results predict that 500 mg of doripenem administered over 1 h every 8 h would be effective ag …
A doripenem population pharmacokinetic model and Monte Carlo simulations were utilized for dose regimen decision support for f …